N-(1-hydroxy-1-phenyl-ethyl amino)-propiophenones

ABSTRACT

COMPOUNDS OF THE FORMULA   R1,R2,R3,((R8,R9-PHENYL)-CH(-R7)-CH(-R6)-N(-R5)-CH2-   CH(-R4)-CO-)BENZENE   IN WHICH:   R1 IS FLUORINE, -CN, -COOH, -COOALK, WHEREIN ALK IS LOWER ALKYL, LOWER ALKYL MERCAPTO OR LOWER ALKYL SULFONYL; R2 AND R3 ARE EACH SELECTED FROM THE GROUP CONSISTING OF HYDROGEN, CHLORINE, BROMINE, LOWER ALKYL, LOWER ALKOXY AND HYDROXY; R4 IS HYDROGEN, METHYL OR ETHYL; R5 IS HYDROGEN OR LOWER ALKYL; R6 IS HYDROGEN OR LOWER ALKYL; R7 IS HYDROGEN OR HYDROXY AND R8 AND R9 ARE HYDROGEN, HALOGEN, LOWER ALKYL, LOWER ALKOXY OR HYDROXY AND THEIR PHARMACOLOGICALLY ACCEPTABLE ACID ADDITION AND QUATERNARY AMMONIUM SALTS WHICH HAVE HEART ACTIVITY, PARTICULARLY IN INCREASING CORONARY BLOOD FLOW AND CONTRACTION AMPLITUDE.

United States Patent O "ice 3,646,145 N-(l-HYDROXY 1-PHEN YL-ETHYL AMINO)- PROPIOPHENONES Kurt Thiele, Frankfurt am Main, Germany, assignor to Deutsche Goldund Silber-Scheideanstalt vormals Roessler, Frankfurt am Main, Germany No Drawing. Filed July 1, 1968, Ser. No. 741,283 Claims priority, application Germany, June 29, 1967, P 93 837.1 Int. Cl. C07c 91/02 US. Cl. 260-570.5 C 6 Claims ABSTRACT OF THE DISCLOSURE Compounds of the formula CH-CH-N-CH-CH- in which:

BACKGROUND OF THE INVENTION Compounds of the formula wherein each of R R and R is H, Cl, NO OH or each of R and R is H or CH and each of R and R is H, Cl, -CH or OCH which are suited for improvement of the heart function have been described in US. Pat. No. 3,225,095.

DESCRIPTION OF THE INVENTION INCLUDING PREFERRED EMBODIMENTS According to the invention it was found that compounds of the following formula, as well as their phar- 3,646,145 Patented Feb. 29, 1972 macologically acceptable acid addition and quaternary ammonium salts in which:

R is fluorine, -CN, -COOH, COOAlk, wherein Alk is lower alkyl, lower alkyl mercapto or lower alkyl sulfonyl;

R and R are each selected from the group consisting of hydrogen, chlorine, bromine, lower alkyl, lower alkoxy and hydroxy;

R is hydrogen, methyl or ethyl;

R is hydrogen or lower alkyl;

R is hydrogen or lower alkyl;

R is hydrogen or hydroxy and R and R are hydrogen, halogen, lower alkyl, lower alkoxy or hydroxy also have valuable pharmacological properties, particularly for heart and circulatory conditions and especially those in which R is as defined, R and R are hydrogen or lower alkoxy, R and R are hydrogen, R is hydrogen or lower alkyl, R is hydroxy and R and R are hydrogen or hydroxy also possess valuable properties in improving the heart func tion.

A more specific class of compounds within the invention is compounds of Formula 1(a) below:

wherein R is selected from the group consisting of F, lower alkyl mercapto and lower alkyl sulfonyl, R is hydrogen or lower alkoxy, R is hydrogen or methyl, and R is hydrogen or hydroxy, and their pharmacologically acceptable acid addition salts.

For sake of simplicity in the following general description of the process for preparing the compounds according to the invention, the radical which also appears at the left end of the Formula I for the compounds according to the invention will be designated as Ph and the radical which also appears at the right end of such formula will be designated as Ph The compounds according to the invention, for example, can be produced by:

(a) reacting a compound of the formula P h o 0 -0H,

R III with a compound of the formula H-NOHCHPh n R iv IV together with formaldehyde or a formaldehyde yielding substance;

(b) reacting a compound of the formula Ph C OOH-CH2Z with a compound of the formula W-CH-CH-Ph E R1 VI in which one of Z and W represents halogen and the other -NHR in the presence of a basic substance;

(c) reacting a compound of the formula or the corresponding Mannich base ic Ph -CH--CH-CHz-N R4 R11 VIII wherein R and R are lower alkyl with a compound of the Formula IV;

(d) reacting a compound of the formula in which Me is alkali metal, MgCl, MgBr or --Mgl with a compound of the formula V-CHCH2NOHCHPh-g 1' B is is in which V is CN or COHal (Hal: C1 or Br).

In procedure (a) temperatures of to 150 C. are usually employed. Solvents such as alcohols, dioxane, glacial acetic acid and the like come into consideration.

Procedure (b) is usually carried out at elevated temperatures, such as, for example, between 80 and 140 C., in a solvent such as an alcohol, ether, dimethyl formamide and the like. Alkali metal alcoholates, alkali metal amides, alkali metal carbonates and tertiary amines, for instance, come into consideration as the basic substances.

Procedure (c) when carried out with unsaturated ketone VII is generally carried out at temperatures between 20 and 80 C. in an inert solvent, such as, ether, acetone, dioxane or chloroform and when carried out with the corresponding Mannich base VIII, which during the reaction intenmediately decomposes to the unsaturated ketone VII is generally carried out at 30 to 120 C. in a solvent such as water, alcohol/water or a two phase system such as water/benzene or water/ toluene.

Procedure (d) is preferably carried out at temperatures between 20 and +80 C. Solvents, such as, ether, dioxane, tetrahydrofurane or benzene come into question.

The compounds according to the invention which contain optically active carbon atoms which usually are obtained as racemates can be separated into their optically active isomers or diastereomers by the normal methods.

However, optically active isomers or diastereomers can also be used as starting materials.

The compounds according to the invention can be converted to their pharmacologically acceptable acid addition salts or quaternary ammonium salts with the aid of such pharmacologically acceptable acids such as acetic, succinic, maleic, fumaric, lactic, hydrochloric, hydrobromic, sulfuric, phosphoric acids or quaternizing compounds such as the lower alkyl halides.

Conversely, when the acid salts are produced as primary products, they may be converted to their free base by treatment with a base such as potassium carbonate.

The compounds according to the invention possess valuable pharmaceutical properties and are suited for the treatment of heart and circulatory conditions and especially for increasing the coronary blood flow in combination with an improvement in the heart function. The compounds were tested on the isolated guinea pig heart following the method of Langendorfi (Pfliigers Arch. 61, 219, 1889) for their activity on coronary blood flow, contraction amplitude and heart frequency. Metabolism investigations on the Langendorif heart have also shown that the increase in contraction amplitude is accompanied by an increased production of energy supplying substrates and improved utilization of the latter. Their toxicity (LD 50 mg.. kg. was

4 tested on mice upon oral application by the method of Miller and Tainter (Proc. Soc. exper. Biol. a. Med. 57, 261, 1944).

The compounds according to the invention produce a moderate to strong dilation of the coronary system with a simultaneous increase in contraction amplitude in a dosage range of l0500 g. hear. They therefore are suited for improving the function of the heart muscle, as Well as the blood flow through the heart muscle.

The administration of the compounds according to the invention is by the standard modes for administration of compounds wlnch are active in improving coronary blood circulation, such as, for example, enteral, parenteral, oral or perlingual. The dosage rate upon intravenous administration to animals, for example, dogs, is in the range of about 0.5-50 mgJkg.

The following examples will serve to illustrate the compounds according to the invention.

EXAMPLE 1 1-3- 1-phenyl-1-hydroxy-propyl-( 2 amino] 1- (2-fluoro-phenyl) -propanonel HCl 10 g. (0.072 mol) of 2-fiuoro acetophenone, 13.6 g. (0.072 mol) of l-norephedrine-HCI and 2.6 g. of paraformaldehyde (0.087 mol) were boiled under reflux for 4 hours in 50 ml. of isopropanol to which 2 drops of isopropanolic I-ICl had been added. Upon cooling the hydrochloride crystallized out. Yield 11 g., melting point l87l89 C. (recrystallized from methanol).

EXAMPLE 2 (a) 1-3- l-phenyl-1-hydroxy-propyl-(2)-amino]- 1- 3-fluoro-phenyl) -propanone-( 1 -HCl 15.2 g. (0.11 mol) of 3-fiuoro acetophe none, 15.1 g. (0.1 mol) of l-norephedrine and 3.6 g. (0.12 mol) of paraformaldehyde were added to 50 ml. of isopropanol and the mixture adjusted to a pH of 4 by the addition of isopropanolic HCl and then boiled under reflux for 3 hours. Upon cooling the hydrochloride salt crystallized out. Yield 21 g., melting point 205208 C. (recrystallized from methanol).

(b) 1-3-[l-phenyl-1-hydroxy-propyl-(2)-amino]-1-(4- fluorophenyl)-propanone-(l)-HCl was prepared analogously using 4-fluoro acetophenone as the starting material. Yield 16 g., melting point 203-206 C. (recrystallized from methanol).

EXAMPLE 3 1-3-[ l-phenyll-hyd roxy-propyl- 2 -amino] l- 3- fiuoro-4-methoxy-phenyl) -propanone-( 1 I-ICl 5 g. (0.03 mol) of 3-fluoro-4-methoxy acetophenone, 6.8 g. (0.036 mol) of l-norephedrine-HCl and 1.8 g. (0.06 mol) of paraformaldehyde were boiled under reflux in 50 ml. of ethanol and ml. of isopropanol in the presence of 2 drops of isopropanolic HCl whereby the hydrochloride salt precipitated out. Yield 5 g., melting point 216-217" C. (recrystallized from methanol) EXAMPLE 4 d,l-3-(2-phenyl-2-hydr0xy ethyl amino)-4-l- (fluoro-phenyl)-propanone-( l 19.5 g. (0.0843 mol) of ,8-dimethylamino-4-fluoro propiophenone-HCl and 11.5 g. (0.0843 mol) of 2-phenyl-2- hydroxy ethyl amine were each dissolved in 100 ml. of water and after mixing warmed to 60 C. Upon cooling, 14 g. of the base (melting point l32l33 C.) precipitated out which was filtered off and washed with ether. The base was then slurried in 300 ml. of isopropanol and converted to the HCl salt with isopropanolic HCl. Yield 14 g., melting point 181-183" C. (recrystallized from ethanol).

EXAMPLE 1-3- l-phenyll-hydroxy-propyl- (2 -amino] 1-(3-carboxy-phenyl)-propanone-( l) -HCl 14.5 g. (0.0884 mol) of 3-carboxy-acetophenone, 16.6 g. (0.0885 mol) of l-norephedrine'Hcl and 5.4 g. (0.18 mol) of paraformaldehyde were boiled in 70 ml. of isopropanol under reflux for one hour whereby the HCl salt precipitated out. Yield 9 g., melting point 208 C. (recrystallized from ethanol).

EXAMPLE 6 1-3- l-phenyl-l-hydroxy-propyl-(Z)-amino] -1- (3-cyano-phenyl)-propanone-(l) -HCl 5 g. (0.0345 mol) of 3-cyano-propi0phenone, 6.5 g. (0.0348 mol) of l-norephedrine-HCl and 1.5 g. (0.05 mol) of paraforrnaldehyde were reacted in 30 m1. of isopropanol as in Example 5. Yield 1.5 g. of the HCl salt, melting point 212 C. (recrystallized from ethanol).

EXAMPLE 7 1-3- 1-phenyl-l-hydroxy-propyl- (2 -amino] -1 3- carbethoxy-phenyl)-propanone-( l -HCl 8 g. (0.0416 mol) of 3-carbethoxy-acetophenone, 7.8 g. (0.0416 mol) of l-norephedrine-HCI and 2.6 g. (0.0867 mol) of paraformaldehyde were boiled under reflux for 2 hours in 50 ml. of isopropanol. After the reaction solu tion cooled down acetone was added, whereupon the HCl salt precipitated out. Yield 2 g., melting point 202 C. (recrystallized from ethanol).

EXAMPLE 8 1-3-[ l-phenyl-l-hydroxy-propyl-(Z) -amino] -1- (4- methylmercapto-phenyl) -propan0ne-( 1 -HCl 16.8 g. (0.1 mol) of 4-methylmercapto-acetophenone, 18.7 g. (0.1 mol) of l-norephedrine-HCI and 6 g. (0.2 mol) of paraformaldehyde were reacted in 50 ml. of isopropanol as in Example 5. Yield 12 g. of the HCl salt, melting point 202204 C. (recrystallized from methanol).

EXAMPLE 9 1-3-[ 1-phenyl-l-hydroxy-propyl-(2)-amino]-l-(4- methyl sulfonyl-phenyl)-propanone-( 1 19.8 g. (0.1 mol) of 4-methyl sulfonyl-acetophenone, 18.7 g. (0.1 mole) of l-norephedrine-HCl and 6 g. (0.2 mol) of paraformaldehyde were reacted in 50 ml. of isopropanol as in Example 5. Yield 17 g. of the HCl salt, melting point 219220 C. (recrystallized from 80% ethanol).

EXAMPLE 10 d.l-3-[ 1, (4-hydroxy-phenyl l-hydroxy-propyl- (2 amino] -1-(4-fluoro-phenyl)propanone-( 1 HCl 13.8 g. (0.1 mol) of 4-fluoro acetophenone, 6 g. (0.2 mol) of paraformaldehyde and 20.3 g. (0.1 mol) of d,lp-hydroxy-norephedrine -HCl were heated under reflux for 6 hours in ml. of ethanol. The solvent was distilled oil and acetone then added to the residue to effect crystallization thereof. The hydrochloride salt was washed with water and recrystallized from isopropanol. Yield 2 g. of the HCl salt, melting point C.

EXAMPLE ll d,l- 1- 4-hydroxy-phenyl) l-hydroxy-propyl- 2 amino] l- 3-cyano-phenyl) -propanone-( 1) HCl wherein R is selected from the group consisting of F, lower alkyl mercapto and lower alkyl sulfonyl, R is hydrogen or lower alkoxy, R is hydrogen or methyl, and R is hydrogen or hydroxy, and their pharmacologically acceptable acid addition salts.

2. A compoun according to claim 1 wherein R is selected from the group consisting of lower alkyl mercapto and lower alkyl sulfonyl.

3. A compound according to claim 1 wherein R is F, methyl mercapto or methyl sulfonyl, R is hydrogen or methoxy.

4. A compound according to claim 1 wherein R is F, R is hydrogen, R is methyl and R is hydrogen.

5. A compound according to claim 1 wherein R is F. R is hydrogen, R is methyl and R is hydroxy.

6. A compound according to claim 1 wherein R is F.

References Cited UNITED STATES PATENTS 3,197,507 7/1965 Freed et a1 260-5705 3,225,095 12/1965 Thiele 260570.5 3,337,546 8/ 1967 Malatestinic et a1.

260570.5 X 3,337,626 8/1967 Thiele 260-5705 ROBERT V. HINES, Primary Examiner US. Cl. X.R.

260465 RE, 501.18, 515 R, 519, 544 R, 544 M, 567.6 M, 570.6, 592; 424298, 304, 309, 329, 330 

